Key stats
About SELECTRA J. LAMARCK BIOTECH CLASS D
Home page
Inception date
Jan 24, 2011
Structure
Luxembourg SICAV
Dividend treatment
Capitalizes
Primary advisor
J Lamarck SpA
ISIN
LU1246176264
The main objective of this Sub-Fund is to profit from increasing share prices in the biotechnology sector. The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like Nasdaq or NYSE.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.48%
Health Technology97.85%
Bonds, Cash & Other1.52%
Mutual fund2.16%
Cash−0.64%
Stock breakdown by region
North America76.94%
Europe23.06%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history